A slight drop in hospital admissions after amyloid PET, especially in people with positive scans, fell well short of the prespecified endpoint. Still, IDEAS is broadening into a research platform, and IDEAS 2 will add racial diversity.
New genetic variants emerged by harmonizing whole-exome-sequencing data across continents, and by using imputation to plumb the depths of existing GWAS. One variant encodes a microglial phospholipid transporter.
In the Alzheimer’s brain, too, plaques trigger a coordinated inflammatory response from microglia and astrocytes. A preprint paper had shown the same for mice.
In large population datasets, people who had been vaccinated against influenza or pneumonia appeared less likely to develop AD.
This early marker distinguishes Alzheimer’s from controls and other neurodegenerative diseases more accurately than other biomarkers.
Poor coordination among grid cells in the entorhinal cortex and place cells in the hippocampus compromises navigation. Grid cells fail first.
This neuronal protein regulates the complement cascade in the developing brain. Could it do the same in aging or neurodegenerative disease?
In striatal spiny projection neurons with mutant huntingtin, mitochondria spill immunogenic RNAs into the cytosol. These touch off innate antiviral signaling inside the neurons, which may spell their demise.
Virtual Exhibit Hall
Alzforum encourages users to visit the Virtual Exhibit Hall, where companies showcase their newest initiatives, products, and services. We welcome F. Hoffmann-La Roche, joining our other exhibitors — Biogen, BioLegend, Dash Genomics, Inc., Abcam, BrainXell, and the Jackson Laboratory.
In two new papers and several presentations at this year’s AAIC, researchers describe how p-tau217 in the plasma distinguishes people with Alzheimer’s disease from healthy controls and from people with related disorders. The test posts a stunning degree of accuracy and boasts a comfortable dynamic range. Plasma p-tau217 levels, which seem specific for people who have just begun to deposit amyloid plaques, begin to rise two decades before symptoms or appreciable neurofibrillary tangles. Will this test transform Alzheimer’s research, drug development, and care?
- Randall Bateman on Plasma p-Tau217 Set to Transform Alzheimer’s Diagnostics
- Kiran Bhaskar and Jason Weick on Neuronal SRPX2 Spoils Microglial Appetite for Synapses
- Cynthia Lemere on Neuronal SRPX2 Spoils Microglial Appetite for Synapses
- Marc Vermulst on Rogue APP Claim Embroiled in Contamination Concerns
- Ekaterina Rogaeva on Rogue APP Claim Embroiled in Contamination Concerns
- Marlene Jimenez-Del-Rio on Does Huntington’s Disease Begin in the Womb?
- Nick Fox on Does Huntington’s Disease Begin in the Womb?
- Sarah Tabrizi on Does Huntington’s Disease Begin in the Womb?
- Tom Davis on Physiological blood-brain transport is impaired with age by a shift in transcytosis.
- Masaru Tanaka on Animal-Assisted and Pet-Robot Interventions for Ameliorating Behavioral and Psychological Symptoms of Dementia: A Systematic Review and Meta-Analysis.
- Michal Schwartz on Cancer Treatment Takes Aim at Tauopathy
- Deepak Nair on γ-Secretase Spotted Traveling Solo or in Pairs, Not in Big Groups
- Jürgen Götz on Blood-Brain Barrier Surprise: Proteins Flood into Young Brain
- Yaakov Stern on Does a Stimulating Childhood Stem Amyloid Plaques in Golden Years?
- Wim Annaert on γ-Secretase Spotted Traveling Solo or in Pairs, Not in Big Groups
- Patrick Fraering on γ-Secretase Spotted Traveling Solo or in Pairs, Not in Big Groups
- Lei Liu and Dennis Selkoe on γ-Secretase Spotted Traveling Solo or in Pairs, Not in Big Groups
- Yuetiva Robles on Women and Men Differ in Their Genetic Risk for Alzheimer’s Progression
- Shahram Oveisgharan on Women and Men Differ in Their Genetic Risk for Alzheimer’s Progression
- Prashanthi Vemuri on Does a Stimulating Childhood Stem Amyloid Plaques in Golden Years?
- Nancy Ip on With IL-33, Neurons Tempt Microglia to Nibble At Synapses